Search Medical Condition
Please enter condition
Please choose location

La Marsa, Tunisia Clinical Trials

A listing of La Marsa, Tunisia clinical trials actively recruiting patients volunteers.

RESULTS

Found (10) clinical trials

Prospective Single-arm Multi Centre Observations Ultimaster Des Registry

All consecutive patients suitable for treatment with DES according to hospital routine practice in centres across the world that agree to participate in the e-ULTIMASTER registry will be treated with Ultimaster DES. Secondary objectives Evaluation of worldwide utilization of DES, Detection of rare events in representative patient population, identification of ...

Phase N/A

0.0 miles

Learn More »

Study to Compare the Efficacy of Pristinamycin (Pyostacine ) Versus Amoxicillin in the Treatment of Acute Community Acquired Pneumonia

The total study duration for each patient is 1 month with a treatment period of 7 to 9 days and a follow-up period of 21 to 23 days.

Phase

8.32 miles

Learn More »

Pharmacokinetic Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency

The present study is designed as a prospective, open-label, multicentre, phase I/III study investigating the 14 day single-dose pharmacokinetic properties, efficacy and safety of BT524 following intravenous administration in the treatment or prophylaxis of bleeding in patients with congenital afibrinogenemia or severe congenital hypofibrinogenemia.

Phase

9.46 miles

Learn More »

Comparison of Thromboembolic Events Between Enoxa and Lovenox in Patients Undergoing Digestive Cancer

Comparative study with two arms versus ENOXA® LOVENOX®, randomized, prospective, single-center, with rater-blinded whose main objective is to compare the incidence of thromboembolic events (symptomatic and asymptomatic) between the two arms of the study, in patients undergoing digestive cancer and receiving thromboprophylaxis based SODIUM enoxaparin.

Phase

9.46 miles

Learn More »

EDS in Ataxia Telangiectasia Patients

All patients who complete the assessments as designed over the initial 6 months of the trial will be eligible to continue in an additional 6-month, double-blind, placebo-controlled extension designed to collect information on the long-term safety and efficacy of the trial treatments. Upon completion of all screening assessments for eligibility ...

Phase

9.46 miles

Learn More »